title: Effects of nafarelin versus danazol on lipids and calcium metabolism.
abstract: This 6-month clinical trial with an additional 12-month follow-up compared the effects of treatment with the gonadotropin-releasing hormone agonist nafarelin and the androgenic agent danazol on lipids and calcium metabolism in women with endometriosis. Of the 23 women who completed the double-blind, double-dummy study, 15 were treated with nafarelin and 8 with danazol. Investigators observed the effects of both agonists on estradiol levels, American Fertility Society endometriosis scores, and side effects. Results indicate that nafarelin seems to be a good alternative to other medications for the treatment of endometriosis and has an acceptable side-effect profile, including metabolic effects.
authors: Department of Obstetrics and Gynecology, Falun Hospital, Sweden.
authors: C
authors: C
authors: Bergquist
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000378:metabolism*; D003613:Danazol / Q000494:pharmacology*; D004715:Endometriosis / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D050356:Lipid Metabolism; D017274:Nafarelin; D011245:Pregnadienes / Q000494:pharmacology*
chemical_list: D011245:Pregnadienes; D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D003613:Danazol; D002118:Calcium